Products

EnsoSleep
EnsoData
Clinical Decision Support & Reference
EnsoSleep is an FDA-cleared, AI-powered, cloud-based solution that optimizes the sleep lab workflow by automating the scoring, viewing, editing, and reporting of Polysomnography (PSG) and Home Sleep Apnea Tests (HSATs). It helps clinicians accelerate diagnosis, improve consistency, and expand patient care.

See all 1 product →

About EnsoData

EnsoData is a U.S.-based healthcare technology company that leverages artificial intelligence (AI) and machine learning (ML) to transform sleep medicine, offering solutions that streamline the diagnosis, treatment, and monitoring of sleep disorders. Their flagship product, EnsoSleep, is an FDA-cleared AI-assisted sleep scoring and study management platform. This platform automates the complex and time-consuming interpretation of polysomnography (PSG) and home sleep apnea test (HSAT) data, significantly reducing the manual scoring time for clinicians—by an average of 62% for PSGs and 68% for HSATs.

For physicians, EnsoData’s technology provides a cloud-based solution that expedites clinical actions across various devices, locations, and teams, enhancing workflow efficiency and enabling remote access to patient therapy data. The platform offers high agreement rates for key metrics such as AHI, SDB, sleep staging, and CSA, ensuring reliable diagnostic analysis. By automating data analysis, EnsoData frees up valuable clinician time, allowing healthcare professionals to focus more on direct patient care, develop new programs, build referral networks, and improve quality reporting initiatives.

Beyond initial diagnosis, EnsoData’s solutions extend to therapy management and remote patient monitoring, aiming to address the significant challenge of undiagnosed and untreated sleep apnea. They are also actively engaged in research and collaborations, such as developing AI-based algorithms for more accurate and scalable diagnosis of narcolepsy type 1 (NT1), further expanding the utility of their waveform AI technology across various neurological and sleep-related conditions.

Focus Areas

AI-powered sleep medicine diagnostic analysis of in-lab and home sleep studies sleep scoring sleep therapy management remote patient monitoring waveform AI improving patient access and affordability

Business Intelligence

Key InvestorsQuesta Capital, Zetta Venture Partners, Venture Investors Health Fund, Supermoon Capital, Inspire Medical Systems, Y Combinator, Sternhill Associates, Colle Capital, HealthX Ventures, M25 Ventures, Dreamit Ventures, SleepScore Ventures, Necessary Ventures
PartnershipsAeroflow, React Health, Parachute Health, Cadwell, LabRetriever, Takeda, Advanced Brain Monitoring, Blackstone Medical, Happy Health, BodiMetrics
TechnologyCloud-native SaaS platform leveraging AI and machine learning for waveform data analysis, deep learning models, interoperable with various sleep diagnostic devices
FDA Clearances2 cleared products (estimated)

What Physicians Need to Know

AI-Powered Sleep Scoring & Analysis
EnsoData's flagship solution, EnsoSleep, is an FDA-cleared and AASM-certified AI-powered platform for diagnostic analysis of in-lab polysomnograms (PSGs) and home sleep apnea tests (HSATs). It automates sleep scoring and staging, event detection, and generates comprehensive reports, significantly reducing manual scoring time.
Home Sleep Testing (EnsoHST)
EnsoHST offers a simple, efficient, and multi-night home sleep testing solution utilizing AI-driven analysis of photoplethysmogram (PPG) signals captured by affordable, non-proprietary pulse oximeters. It expands patient access to diagnosis, supports up to 7 nights of testing, and provides accurate, unbiased results.
Sleep Therapy Management (Therapy Track)
EnsoData's Therapy Track solution, powered by EnsoHST, provides AI-driven remote physiological monitoring (RPM) to seamlessly connect diagnosis to therapy. It enables clinicians to monitor patient success longitudinally across various treatment modalities (CPAP, GLP-1s, HGNS, oral appliances) using a single PPG-based device and the Celeste+ mobile application.
Remote Patient Monitoring (RPM)
Through its Therapy Track offering, EnsoData facilitates continuous remote monitoring of patients using comfortable, non-invasive devices (ring, watch, patch form factors). This allows for proactive intervention, at-home titrations, and improved long-term patient outcomes.
Waveform AI Expertise
EnsoData specializes in Waveform AI, a core technology that performs complex and time-consuming data interpretation and analysis across various physiological signals, including EEG, EKG, Pulse Ox, EMG, EOG, Airflow, Respiratory Effort, and Actigraphy.
Improving Patient Access & Affordability
By leveraging AI-powered solutions and affordable, reusable PPG-based devices, EnsoData aims to simplify the sleep care pathway, reduce costs, and accelerate the diagnosis and treatment of sleep disorders, addressing the large population of undiagnosed patients.
Physician Tip

For physicians, EnsoData stands out by significantly expediting the diagnosis and treatment process for sleep disorders. EnsoSleep reduces sleep study scoring time by an average of 62% for PSGs and 68% for HSATs, allowing for faster turnaround of results and quicker initiation of treatment. The cloud-based platform offers a unified view for reviewing, editing, and generating reports for all in-lab and home sleep studies, regardless of device manufacturer, from any location without a VPN. This improves workflow efficiency, standardizes scoring results, and increases confidence in HSAT outcomes, especially with the accurate Total Sleep Time (TST) calculation. The ePrescribing integration with platforms like Parachute Health further streamlines the ordering of therapy, reducing manual data entry and accelerating patient access to treatment. Ultimately, EnsoData frees up valuable clinician time to focus on enhanced patient care, follow-up on treatment, and expand services, including pediatric care.

EnsoData's solutions are designed to be interoperable and compatible with most leading sleep diagnostic in-lab and home sleep testing devices, ensuring seamless integration into existing sleep lab workflows. They offer specific integrations, such as with Parachute Health for ePrescribing, which automates the population of order details from sleep studies into the prescription platform. Additionally, platforms like Keragon can be used for HIPAA-compliant automations, allowing EnsoData to connect with over 300 other tools for various healthcare workflows.

Products by EnsoData

1 product in the directory

EnsoSleep
EnsoData
Clinical Decision Support & Reference
EnsoSleep is an FDA-cleared, AI-powered, cloud-based solution that optimizes the sleep lab workflow by automating the scoring, viewing, editing, and reporting of Polysomnography (PSG) and Home Sleep Apnea Tests (HSATs). It helps clinicians accelerate diagnosis, improve consistency, and expand patient care.

What the Web Says

EnsoData is a healthcare technology company that utilizes artificial intelligence to streamline and enhance the analysis of sleep study data, primarily through its product EnsoSleep. Reviews indicate that the software is highly effective in automating sleep study scoring, reducing turnaround times, and improving efficiency for healthcare providers. The company is generally viewed positively for its innovative AI solutions and supportive customer service.

Overall: Positive

Strengths

  • EnsoSleep accurately scores sleep studies, often within 15 minutes.
  • The software significantly reduces turnaround time for sleep study results.
  • It helps decrease costs and improve the scalability of sleep lab operations.
  • EnsoData's customer support is highly responsive and helpful.
  • The platform is easy to use and integrates well with existing systems.
  • AI-powered scoring frees up time for clinicians to focus on patient care and program development.

Limitations

  • Some users have experienced initial difficulties with integration, particularly with EMR systems like EPIC.
  • The transfer process for data can sometimes be less seamless, partly depending on the client's HIT department.
  • The AI, while accurate, may require some manual re-scoring for certain events, such as N3 sleep stages or differentiating central vs. obstructive respiratory events in studies with artifacts.
  • The software does not currently score 'Mixed' respiratory events, requiring manual adjustment.
  • One review mentioned that new updates have made customized options less user-friendly.
  • There is a desire for the software to detect poor channels and adjust accordingly for analysis.

Based on reviews from: G2, Capterra, SimplyHired, Zippia, SourceForge, EnsoData Website, Reddit

Last updated: 2026-07-18

Videos

News, demos, and interviews about EnsoData.

Loading videos...

Videos load interactively. If none appear, search YouTube for EnsoData →

View all on YouTube

Press & Coverage

EnsoData
EnsoDatau2122 Raises $20M Series B to Expand Commercial Team
EnsoData announced a $20 million Series B financing round led by Questa Capital to accelerate the adoption of its AI-powered sleep medicine solutions and expand its commercial team. The funding will help address the estimated 54 million patients in the US suffering from sleep apnea, with a focus on improving diagnosis and treatment.
2025-06
EnsoData
EnsoData Announces Collaboration with Takeda to Improve Narcolepsy Type 1 Diagnostic Journey Using AI Tools and Technology
EnsoData is collaborating with Takeda to develop and validate AI-based polysomnography (PSG) algorithms for more accurate and scalable diagnosis of narcolepsy type 1 (NT1). This partnership aims to integrate these algorithms into EnsoData's cloud platform to enhance clinical workflows for NT1 diagnosis and follow-up care.
2025-08
HME News
EnsoData Launches AI-Powered Remote Physiological Monitoring
EnsoData has introduced a new remote physiological monitoring (RPM) offering within its EnsoSleep PPG ecosystem of AI tools. This solution enables clinicians to continuously monitor patients at home using comfortable wearable devices, facilitating proactive intervention and improved therapy management for sleep-disordered breathing.
2025-05
PR Newswire
Latest EnsoData FDA 510(k) Clearance Enables AI-Powered Sleep Diagnosis Using Pulse Oximetry Devices
EnsoData received FDA 510(k) clearance for technology that allows AI-powered sleep diagnosis using widely available pulse oximetry devices. This advancement, powered by EnsoHST scoring, aims to make sleep disorder diagnosis more accessible and cost-effective, particularly for conditions like sleep apnea.
2024-02
PR Newswire
EnsoData expands sleep apnea screening and diagnosis capabilities with new acquisition
EnsoData acquired sleep testing diagnostic technology from Resonea, integrating acoustic flow and microphone data channels into its platform. This acquisition enables new ways to pre-screen patients for sleep apnea using an FDA-cleared mobile application and extends the diagnostic capabilities of home sleep testing.
2024-07
EnsoData
EnsoData, Nonin Partner to Offer Affordable, Non-Invasive at Home Sleep Testing for Patients at Risk of Sleep Apnea
EnsoData partnered with Nonin to provide affordable, non-invasive at-home sleep testing for sleep apnea patients. This collaboration combines EnsoHST software with Nonin's WristOx2u00ae Model 3150 device, allowing AI to analyze data and provide sleep staging and event detection analysis.
2024-08
Business Wire
CIBC Innovation Banking Provides Growth Capital to EnsoData
CIBC Innovation Banking has provided growth capital financing to EnsoData, a leading provider of AI-powered software solutions for sleep medicine. This funding will support EnsoData's expansion of access to sleep care and accelerate investment in AI-driven innovations across multiple clinical domains.
2026-05
HME News
EnsoData adds position data to sleep test
EnsoData's FDA-cleared EnsoSleep PPG home sleep test now includes position data from Advanced Brain Monitoring's Night Shift sleep positioner. This integration provides a more comprehensive diagnostic picture for sleep apnea patients, especially those with positional sleep apnea, and aims to personalize therapy recommendations.
2025-05

Frequently Asked Questions

EnsoData's AI, EnsoSleep, automates the scoring of in-lab and home sleep studies, significantly reducing manual review time for technologists and physicians. This automation improves consistency and accuracy in diagnoses, allowing clinicians to focus more on patient care rather than tedious scoring tasks.
EnsoData offers EnsoSleep for diagnostic analysis and EnsoHST for home sleep testing, which includes Therapy Track for managing sleep therapy. Therapy Track leverages AI to help optimize therapy initiation and adherence, while also supporting remote patient monitoring capabilities to track patient progress and engagement.
EnsoData prioritizes HIPAA compliance and robust data security measures to protect patient information. Their solutions are designed for seamless integration with existing EMRs and sleep lab systems, minimizing disruption and ensuring a smooth transition for clinical staff.
By streamlining the diagnostic process and reducing the time to diagnosis, EnsoData can help increase the capacity of sleep labs, thereby improving patient access. The efficiency gains and use of cost-effective home sleep testing solutions can also lead to cost savings for providers, potentially translating to more affordable care options.
EnsoData provides comprehensive support, including dedicated implementation specialists to ensure a smooth onboarding process and ongoing technical assistance. They work closely with organizations to integrate their AI into existing workflows and provide training for clinical staff.
EnsoData has a strong track record as a leader in AI-powered sleep medicine, backed by significant investment and a growing customer base. They actively pursue partnerships with leading healthcare organizations and technology providers like React Health, Nonin, and Blackstone Medical Services to expand their reach and enhance their offerings.

Investors

Who's funded EnsoData.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.